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ABSTRACT
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare cause of pulmonary 
hypertension; less than 5% of pulmonary hypertension is caused by recurrent pulmonary 
thromboembolism (PTE). By definition, CTEPH happens within the first two years after 
symptomatic PTE; however, cases are often diagnosed without a history of acute PTE. 
Because of the poor functional status and chronicity of this disease, the classic and curative 
strategy of open pulmonary endarterectomy cannot be applied in some patients with 
lesions that involve the distal subsegmental pulmonary artery. Bridging therapy is needed 
for cases that are technically operable but have an unacceptable risk-benefit assessment 
or residual symptomatic pulmonary hypertension following surgical removal. Groups in 
Europe and Japan recently introduced balloon pulmonary angioplasty or percutaneous 
transluminal pulmonary angioplasty, which has led to significant improvement in 
functional and hemodynamic parameters in patients with CTEPH. This article introduces 
recent updates in patient selection and interventional procedures for this chronic and 
devastating disease.
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INTRODUCTION
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare cause of pulmonary 
hypertension that presents as obstructive pulmonary artery remodeling with organized and 
fibrotic changes as a consequence of acute pulmonary thromboembolism (PTE). CTEPH 
develops in about five individuals per million annually and in 0.56% to 6.1% of individuals 
after acute thromboembolism.1-4) By definition, CTEPH occurs within the first two years after 
the initial symptomatic PTE event, and it usually occurs three to six months after this event. 
However, cases are frequently not associated with a previous history of acute PTE. Chronic 
thromboembolic disease (CTED) is a similar entity that can be diagnosed regardless of 
pulmonary hypertension.5) Because of the poor functional status and chronicity of CTEPH, 
the classic and curative strategy of open pulmonary endarterectomy (PEA) cannot be applied 
in some patients with lesions involving distal vessels.1) Balloon pulmonary angioplasty (BPA) 
or percutaneous transluminal pulmonary angioplasty (PTPA) were recently introduced by 
groups in Europe and Japan for use in these inoperable cases, which has led to significant 
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improvement in functional and hemodynamic status in patients with CTEPH.6)7) In South 
Korea, there are recent reports of early outcomes after BPA and multidisciplinary approaches 
in patients with CTEPH.8)9)
PATHOPHYSIOLOGY OF CHRONIC THROMBOEMBOLIC 
PULMONARY HYPERTENSION
Pathophysiologically, thrombotic occlusion of the pulmonary artery results in high 
pulmonary vascular resistance that causes right heart overload and failure of right heart 
that eventually impacts normal activity. Risk factors for the development of CTEPH include 
recurrent embolic events, initial high pulmonary artery pressure at diagnosis, hemostatic 
risk factors such as antiphospholipid antibody syndrome, lupus disease, and other medical 
conditions.1)4) Guidelines for diagnosis of CTEPH recommend the presence of sustained 
thrombotic burden even after three months of anticoagulation to discriminate subacute 
disease from CTEPH.5) This diagnostic approach is based on the pathophysiology of the 
disease; however, these diagnostic criteria are not clinically applicable for all cases of CTEPH.
In contrast to acute thrombi, surgical specimens of patients with CTEPH showed 
complex patterns which are more organized, fibrotic and it attached firmly to the wall 
of the pulmonary artery and largely consist of collagen, elastin, inflammatory cells, and 
recanalization vessels. The exact mechanism of these organized and fibrotic changes 
are not yet fully known. However, initial inadequate and inappropriate anticoagulation 
affects this process of chronicity, as do underlying autoimmune disease, hematological 
abnormalities, or hypercoagulable tendencies.10) Organized and fibrotic occlusion of the 
pulmonary artery causes macrovascular obstruction and vasoconstriction, which can 
provoke sustained remodeling of vasculature even after normalization of pulmonary artery 
pressure with treatment.11) Remodeled small vessels are pathologically similar to idiopathic 
pulmonary arterial hypertension and demonstrate compatible structural changes as right-
sided heart overload.
DIAGNOSIS
Baseline evaluations usually include cardiopulmonary exercise testing with oximetry and 
maximal oxygen uptake, six minute walk test, ventilation/perfusion lung scanning, computed 
tomography (CT) pulmonary angiogram, and echocardiographic assessment of right heart 
function. These test results are crucial for initial decisions and follow-up. According to the 
2015 European guidelines, diagnosis of CTEPH begins by assessing symptoms and signs 
and obtaining echocardiography.5) If there is high or intermediate probability, a ventilation/
perfusion lung scan is required to detect areas of malperfusion.12)13) The gold standard 
and final confirmation of CTEPH is selective angiogram with right heart catheterization. 
CT pulmonary angiography does not provide sufficient information because perfusion is 
dependent on visualizing small vessels. CT is usually used when deciding on the operability 
of CTEPH by assessing major vessel involvement. Contrary to other entities of pulmonary 
hypertension, patients that are properly diagnosed with CTEPH can dramatically improve 
after correction of the causative thrombotic barrier. A differential diagnosis of CTEPH should 
be considered, including peripheral pulmonary stenosis or pulmonary vasculitis causing 
pulmonary artery stenosis, such as Takayasu disease.
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TREATMENT MODALITY OF CHRONIC 
THROMBOEMBOLIC PULMONARY HYPERTENSION
PEA is the treatment of choice in patients with CTEPH.  One-third of CTEPH cases are 
inoperable due to co-morbidities or distal lesions, which are signs of poor prognosis. 
Percutaneous pulmonary artery procedures can be used in patients who cannot undergo 
which are signs of poor prognosis PEA due to comorbid conditions or distal disease 
localization, and this procedure is now being introduced in many parts of the world. In 
addition to inoperability, bridging therapy is also needed for cases that are technically 
operable but have unacceptable risk-benefit or residual symptomatic pulmonary hypertension 
following surgical removal.1)
BALLOON PULMONARY ANGIOPLASTY FOR CHRONIC 
THROMBOEMBOLIC PULMONARY HYPERTENSION
First procedure
The first case series of balloon pulmonary angioplasty in patients with CTEPH was published 
in 2001.6) Feinstein et al.6) reported 18 patients with 47 procedure sessions and an average 
of 2.6 procedures per patients. They showed remarkable improvement in hemodynamic 
parameters and functional capacity; however, 11 of 18 cases were complicated by reperfusion 
pulmonary edema, and some patients required mechanical ventilation and died. Consecutive 
outcomes of BPA were rarely reported, and the 2009 European guidelines for pulmonary 
hypertension did not comment on angioplasty for CTEPH.13)
Current trends in balloon pulmonary angioplasty and practice guideline 
recommendations
After early reports of BPA, Matsubara et al.7) tried to reduce complications of BPA and 
reported better outcomes for CTEPH after 2012. Of the 255 patients who underwent 
the initial BPA procedures, 76 had reperfusion pulmonary edema, 4 of which required 
mechanical ventilation and one mortality was reported. After this report, they continued 
to try to improve the safety of BPA. First, they used low profile balloon angioplasty with a 
2.0 mm diameter for patients with high mean pulmonary pressure over 40 mmHg. After 
several sessions of BPA for as many lesions as possible, progressively larger balloons were 
used for residual and selected lesions. They attained better hemodynamic outcomes and 
functional capacity compared to their initial report. By this methodology, complications were 
significantly reduced and BPA could be considered an alternative strategy for inoperable, 
disabled CTEPH cases. Until now BPA as for CTEPH is class IIb recommendation by 2015 
guideline, it is accepted as more favorable strategy according to current expert opinion.5)11)15)16)
Recent clinical multicenter registry data in Japan showed more promising improvements in 
functional classes and echocardiographic parameters. A total of 308 patients (246 women; 
mean age 61 years) were included in this retrospective registry; patients underwent 1,408 
sessions of BPA at seven institutes. Over 80% of patients showed hemodynamic improvement 
in which mean PAP decreased from 43.2±11.0 to 24.3±6.4 mmHg after final BPA and to 
22.5±5.4 mmHg at outpatient follow-up.14) A multidisciplinary team (MDT) approach is 
crucial for diagnosis and treatment of CTEPH in an experienced center. Recommendations 
stipulate that over 50 cases of PEA and 100 sessions of BPA should be performed per year 
at experienced centers.15) A recent report showed that MDT approach for CTEPH has a 
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significant influence on diagnosis, workup, and decisions regarding therapeutic modality 
such as PEA or BPA.9) In the post-MDT era, the implementation rates of RHC (10.8% vs. 
97.6%, p<0.001) and PEA (32.4% vs. 59.5%, p<0.005) were significantly increased in 
conjunction with the initiation of BPA procedures.
Pulmonary angiogram, selection of patients and lesions
Selective pulmonary angiograms are important when diagnosing CTEPH because CT scans 
and lung perfusion scans cannot show clear information regarding the status of affected 
segmental arteries or subsegmental branches. Selective pulmonary angiogram is usually 
performed via biplane projection by anterior-posterior (AP) and left anterior oblique (LAO) 
60-degree view with a usual coronary Judkins-right or multipurpose catheter. Comprehensive 
anatomy of the pulmonary artery is described in Figure 1 by AP/LAO projection. The Amplatz-
left catheter is helpful for the selection of branches at the left upper and lingular segments 
because of its posterior to anterior projection. Because many branches should be visualized 
to confirm involvement by CTEPH, contrast media should be diluted with saline, especially 
for patients with chronic kidney disease.
Vascular lesions in patients with CTEPH have various morphology, and some experts have 
suggested lesion classification according to these characteristics (Figure 2). Lesions were 
categorized as angiographic morphology, ring-like stenosis, intravascular web, subtotal 
occlusion with small channel and pouch defect, and total occlusive lesion. Lesions with 
chronic total occlusion also have collateral circulation from other branches. Some segments 
of the treated artery showed marked dilation with reduced pulmonary artery pressure after 
follow-up angiogram (Figure 3). The usual mechanisms of dilation are thought to be due to 
compression of organized thrombi by ballooning of the multi-channel lumen and formation 
of neointima that covers the opened luminal surface.16)
Peri-procedural medical therapy including anticoagulation
Patients with CTEPH have a tendency for frequent recurrent thrombosis, and it is crucial to 
maintain patients on anticoagulants before and after procedures. The usual maintenance 
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Figure 1. Basic anatomy of pulmonary artery by angiogram according to projection, either posterior-anterior or left anterior oblique 60 degree. 
LA = left pulmonary artery; RA = right pulmonary artery.
medications are vitamin K antagonists. New anticoagulants (novel oral anticoagulant) 
showed compatible efficacy for acute pulmonary embolism; however, there is no randomized 
trial regarding novel anticoagulants compared to vitamin K antagonists in CTEPH.17) 
Anticoagulation should be sustained at international normalized ratio 2.0–3.0 with warfarin. 
After the first BPA session for both sides of the pulmonary artery, the second and third 
BPA sessions occur at intervals of one to three months depending on clinical condition. 
Intravenous heparinization before a procedure should be administrated in minimum amount 
to adjust the activated coagulation time (ACT) around 250 seconds for preventing device-
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Intravascular web Ring like stenosis CTO with collateral
Subtotal occlusion Total occlusion Tortuous/distal type
Figure 2. Classification of lesion morphology by angiogram. Various morphology types are detected by angiogram 
in patients with chronic thromboembolic pulmonary hypertension: intravascular web, ring-like, subtotal, and 
total occlusion types. CTO with collateral circulation or diffuse tortuous/distal type is also observed. 
CTO = chronic total occlusion.
Pre Post
Figure 3. Angiogram before and 1 month after balloon pulmonary angioplasty in patients with chronic 
thromboembolic pulmonary hypertension.
related thrombosis and should then be added 500 IU regularly as an hour passes. Riociguat, 
a soluble guanylate cyclase agonist, is the only medical therapy approved for patients with 
inoperable CTEPH to improve right heart overload 18); however, it is still very expensive and is 
not covered by medical insurance in South Korea.
Balloon pulmonary angioplasty equipment
Dual long-sheath and guiding catheters are needed for BPA procedures because the stable 
position of the long-sheath at the main pulmonary artery provides support to guide 
catheter movement when selecting each segmental pulmonary artery (Figure 4). Routine 
0.014 inch soft peripheral wires are acceptable for the procedure. Although dedicated 
wires with soft tips were introduced to support balloon passage for BPA, they cannot 
penetrate some hard and complete occlusive lesions. Hard and high torqueable wires 
should be used for tough lesions, although they may provoke vascular injury in the fragile 
pulmonary artery system. Appropriate diagnostic and guiding catheters vary according 
to the anatomy of individuals. The usual recommended catheters are listed in Table 1. As 
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Y-connector
Guiding catheter
Long sheath 6–7Fr- 80 cm
(shuttle/ansel)
9Fr femoral vein sheath
Extension line
Figure 4. Sheath and guiding catheter system. Dual long-sheath and guiding catheters are needed in balloon 
pulmonary angioplasty procedures because the stable position of the long-sheath at the main pulmonary artery 
provides support to guide catheter movement in selection of each segmental pulmonary artery.
Table 1. Guiding and diagnostic catheters for selective angiogram
Right PA Catheter Left PA Catheter
A1 MP, JR A1+2 MP, AL-1, JR
A2 MP, JR
A3 MP A3 AL-1, JL
A4 MP A4 AL-1, JL
A5 AL-1 > MP A5 AL-1, JL
A6 MP A6 MP, AL-1
A7 MP, JR
A8 MP A8 AL-1, MP
A9 MP A9 AL-1, MP
A10 MP A10 AL-1, MP
AL = Amplatz left; JL = Judkins left; JR = Judkins right; MP = Multipurpose; PA = pulmonary artery.
previously mentioned, balloon angioplasty is usually performed starting with a low profile 
catheter and progressively upsizing to a larger one according the mean pulmonary artery 
pressure. The first device chosen for the initial session may be a 2.0×20 mm balloon, and 
then balloons with up to 6-7 mm diameter can be used in the following sessions depending 
on lesion size. Experienced centers may start with a larger balloon in the first procedure. 
Even with this methodology, the complication rate can be low if a delicate procedural 
approach is used, especially with cases of mild to moderate pulmonary hypertension. 
Table 2 notes the upper limit of the balloon to external elastic membrane diameter ratio in 
the second dilation. Pulmonary stenting is not routinely used for angioplasty in CTEPH; 
however, if there is concomitant pulmonary artery stenosis or lesions that do not respond 
to large balloons, pulmonary stenting can be added as a salvage method in rare cases. The 
main target lesion should be in the segmental or subsegmental pulmonary artery. Despite 
a recognized correlation with pre-BPA mean pulmonary artery pressure over 40 mmHg, 
the extent and potential severity of reperfusion lung injury warrants anticipation of its 
occurrence in all patients with BPA. Mean cardiac index did not improve after BPA despite 
symptomatic improvement and patient survival. Balloon angioplasty began gently with a 
low profile 2.0 mm balloon for all possible branches. To prevent complications, right and 
left pulmonary arteries should be treated separately at intervals of 5–7 days. Proper wire 
positioning and knuckle wire techniques are required to penetrate lesions, and smaller or 
proportionate balloon size to the vessel is necessary to prevent perforation or bleeding. 
In cases with hybrid procedures after PEA, at least three months of durations for vascular 
healing after operation are needed to attain proper outcomes and safety compatible with 
the conventional procedures.
Monitoring before and after treatment, procedure complications and outcomes
Right heart catheterization (RHC) including mean pulmonary artery pressure and 
pulmonary vascular resistance are routine parameters used to monitor improvements in 
this procedure. However, changes in cardiac output or index are relatively equivocal because 
functional improvement in the left heart is relatively independent of right heart unloading. 
Echocardiography should be regularly monitored because it can impact procedural 
decisions and visualize structural changes in patients with CTEPH. Usual causes of 
pulmonary artery injury during BPA are distal vascular injury by guidewires or overdilation 
of stenotic lesions by mismatched balloon size.19) Although there are no randomized 
trials of BPA, single center or multicenter registry reports guided by various modalities 
are useful references for the outcomes and complications of BPA after 2012.7)14)20)21) 
Complications during procedures occurred in 36.3% (511 in 1408 procedures) of cases 
and included pulmonary injury (17.8%) and hemoptysis (14.0%).14) Wire or reperfusion-
induced hemoptysis can be disastrous, and some cases even required tracheal intubation 
and extracorporeal membrane oxygenation. However, reperfusion-induced hemoptysis 
was usually mild and frequently occurred after BPA, especially in patients with high mean 
pulmonary artery pressure over 40 mmHg. The other minor pulmonary dissection or 
thrombosis occurred in some series during the procedures.
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Table 2. Usual recommended upper limit of balloon to EEM ratio according to mPA
Type of lesion
Balloon to EEM ratio (%)
mPA <40 mmHg mPA >40 mmHg
Ring-like stenosis 100 80
Intravascular web 80 64
Complete obstruction 60 48
EEM = external elastic membrane; mPA = mean pulmonary artery pressure.
SUMMARY
BPA is a new alternative treatment option for selected patients with inoperable cases of 
CTEPH. There were initial reports of potentially life-threatening bleeding complications after 
initial reperfusion therapy with BPA. However, recently updated procedures and management 
techniques are relatively safe, and patients with inoperable CTEPH can approach full 
recovery. A multidisciplinary CTEPH team should be involved in the process of investigating 
and establishing PEA and BPA for treatment of this chronic disabling condition.
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